{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T21:01:43Z","timestamp":1766005303245,"version":"3.48.0"},"reference-count":14,"publisher":"American Society of Clinical Oncology (ASCO)","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Rising cancer incidence and staff shortages demand more efficient outpatient oncology workflows. Pembrolizumab is conventionally administered over 30 minutes. This prospective study assessed the safety and patient experience of reducing pembrolizumab infusion duration to 10 minutes to enhance outpatient oncology workflow efficiency.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>In this prospective single-center study at a large Dutch teaching hospital, adults receiving pembrolizumab for any approved indication were eligible if they had no history of grade \u22652 infusion-related reactions (IRRs). After two standard 30-minute infusions without IRRs, durations were reduced to 15 and subsequently 10 minutes. Vital signs were monitored pre- and post-infusion. Adverse events were graded per Common Terminology Criteria for Adverse Events v5.0. Pembrolizumab trough levels and patient-reported experience measures were collected. The primary end point was the incidence of grade \u22652 IRRs during shortened infusions, with safety predefined as &lt;10%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Of 97 enrolled patients, 78 completed the protocol; discontinuation mainly resulted from disease progression or unrelated adverse events. One patient (1.1% [95% CI, 0.0 to 6.1]) experienced a grade 2 IRR during shortened infusions; no grade \u22653 IRRs occurred. Most patients reported high satisfaction, and over 150 hours of outpatient infusion unit capacity were saved.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Ten-minute pembrolizumab infusions are safe and well tolerated and enhance both patient satisfaction and outpatient efficiency.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/op-25-00918","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T20:59:06Z","timestamp":1766005146000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Safety, Feasibility, and Patient Experience of Ten-Minute Pembrolizumab Infusions: A Prospective Cohort Study"],"prefix":"10.1200","clinical-trial-number":[{"clinical-trial-number":"nct06031233","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4314-5106","authenticated-orcid":true,"given":"Elianne C.S.","family":"de Boer","sequence":"first","affiliation":[{"name":"Isala Oncology Center, Isala Hospital, Zwolle, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helle-Brit","family":"Fiebrich-Westra","sequence":"additional","affiliation":[{"name":"Isala Oncology Center, Isala Hospital, Zwolle, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gijs M.M.","family":"Lenis","sequence":"additional","affiliation":[{"name":"Isala Oncology Center, Isala Hospital, Zwolle, the Netherlands"},{"name":"Department of Medical Oncology, University Medical Center Groningen, Groningen, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6640-9448","authenticated-orcid":true,"given":"Peter M.J.","family":"Plomp","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Disease, Isala Hospital, Zwolle, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5449-5035","authenticated-orcid":true,"given":"Mireille A.","family":"Edens","sequence":"additional","affiliation":[{"name":"Epidemiology Unit, Department Innovation and Science, Isala Hospital, Zwolle, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3219-253X","authenticated-orcid":true,"given":"Dirk-Jan A.R.","family":"Moes","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy &amp; Toxicology, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8533-9233","authenticated-orcid":true,"given":"Jan Gerard","family":"Maring","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Isala Hospital, Zwolle, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1043-5011","authenticated-orcid":false,"given":"Jan Willem. B.","family":"de Groot","sequence":"additional","affiliation":[{"name":"Isala Oncology Center, Isala Hospital, Zwolle, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5694-9758","authenticated-orcid":true,"given":"Elise J.","family":"Smolders","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Isala Hospital, Zwolle, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"e_1_3_9_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.43198"},{"key":"e_1_3_9_3_2","volume-title":"Summary of Product Characteristics","author":"European Medicines Agency","unstructured":"European Medicines Agency: Summary of Product Characteristics. Keytruda. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/keytruda-epar-product-information_en.pdf"},{"key":"e_1_3_9_4_2","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-24-111"},{"key":"e_1_3_9_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.03.012"},{"key":"e_1_3_9_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2542-5196(24)00245-6"},{"key":"e_1_3_9_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824"},{"key":"e_1_3_9_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv383"},{"key":"e_1_3_9_9_2","unstructured":"Prescribing information KEYTRUDA\u00ae (pembrolizumab) for injection for intravenous use. FDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125514s047lbl.pdf"},{"key":"e_1_3_9_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx216"},{"key":"e_1_3_9_11_2","unstructured":"SERVICES USDOHAH: Common terminology criteria for adverse events (CTCAE). 2017. Contract No.: Report"},{"key":"e_1_3_9_12_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph14080796"},{"key":"e_1_3_9_13_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9060621"},{"key":"e_1_3_9_14_2","article-title":"Beyond infusion: Real-world insights into infusion-related reactions in monoclonal antibody therapy","author":"Smolders EJ","year":"2025","unstructured":"Smolders EJ, de Boer EC, Fiebrich-Westra HB, Plomp PMJ, et al: Beyond infusion: Real-world insights into infusion-related reactions in monoclonal antibody therapy. JCO Oncol Pract 2025. 10.1200\/OP-25-00275","journal-title":"JCO Oncol Pract"},{"key":"e_1_3_9_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115373"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP-25-00918","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T20:59:07Z","timestamp":1766005147000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP-25-00918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":14,"alternative-id":["10.1200\/OP-25-00918"],"URL":"https:\/\/doi.org\/10.1200\/op-25-00918","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"2025-08-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"OP-25-00918"}}